Author:
Jospe Michelle R.,Liao Yue,Giles Erin D.,Hudson Barry I.,Slingerland Joyce M.,Schembre Susan M.
Abstract
BackgroundHigh glycemic variability (GV) is a biomarker of cancer risk, even in the absence of diabetes. The emerging concept of chrononutrition suggests that modifying meal timing can favorably impact metabolic risk factors linked to diet-related chronic disease, including breast cancer. Here, we examined the potential of eating when glucose levels are near personalized fasting thresholds (low-glucose eating, LGE), a novel form of timed-eating, to reduce GV in women without diabetes, who are at risk for postmenopausal breast cancer.MethodsIn this exploratory analysis of our 16-week weight loss randomized controlled trial, we included 17 non-Hispanic, white, postmenopausal women (average age = 60.7 ± 5.8 years, BMI = 34.5 ± 6.1 kg/m2, HbA1c = 5.7 ± 0.3%). Participants were those who, as part of the parent study, provided 3–7 days of blinded, continuous glucose monitoring data and image-assisted, timestamped food records at weeks 0 and 16. Pearson’s correlation and multivariate regression were used to assess associations between LGE and GV, controlling for concurrent weight changes.ResultsIncreases in LGE were associated with multiple unfavorable measures of GV including reductions in CGM glucose mean, CONGA, LI, J-Index, HBGI, ADDR, and time spent in a severe GV pattern (r = −0.81 to −0.49; ps < 0.044) and with increases in favorable measures of GV including M-value and LBGI (r = 0.59, 0.62; ps < 0.013). These associations remained significant after adjusting for weight changes.ConclusionLow-glucose eating is associated with improvements in glycemic variability, independent of concurrent weight reductions, suggesting it may be beneficial for GV-related disease prevention. Further research in a larger, more diverse sample with poor metabolic health is warranted.Clinical trial registration: ClinicalTrials.gov, NCT03546972.
Reference46 articles.
1. Correlation between oxidative stress, nutrition, and Cancer initiation;Saha;Int J Mol Sci,2017
2. Diabetes and cancer I: risk, survival, and implications for screening;Onitilo;Cancer Causes Control,2012
3. Diabetes mellitus, hyperglycaemia and cancer;Simon;Diabetes Metab,2010
4. Assessment of glucose variability in subjects with prediabetes;Chakarova;Diabetes Res Clin Pract,2019
5. Glucose variability in subjects with normal glucose tolerance: relations with body composition, insulin secretion and sensitivity;Klimontov;Diabetes Metab Syndr,2022